Increased tumor cell expression of Axl is a marker of aggressive features in breast cancer among African women-Reference-Cited by-同舟云学术

Increased tumor cell expression of Axl is a marker of aggressive features in breast cancer among African women

Published:2015-05-25 Issue:8 Volume:123 Page:688-696
ISSN:0903-4641
Container-title:APMIS
language:en
Short-container-title:APMIS

Author:

Ahmed Lavina¹²,Nalwoga Hawa¹,Arnes Jarle B.³,Wabinga Henry⁴,Micklem David R.²,Akslen Lars A.¹³

Affiliation:

1. Centre for Cancer Biomarkers CCBIO; Department of Clinical Medicine; University of Bergen; Bergen Norway

2. BerGenBio AS; Bergen Norway

3. Department of Pathology; Haukeland University Hospital; Bergen Norway

4. Department of Pathology; Makerere University College of Health Sciences; Kampala Uganda

Funder

Norges Forskningsråd

Publisher

Wiley

Subject

Microbiology (medical),General Medicine,Immunology and Allergy,Pathology and Forensic Medicine

Reference51 articles.

1. Epidemiology of breast cancer;Key;Lancet Oncol,2001

2. Ferlay J Soerjomataram I Ervik M Dikshit R Eser S Mathers C GLOBOCAN 2012 v1.0 Lyon, France International Agency for Research on Cancer 2013 http://globcan.iarc.fr

3. Breast cancer as a systemic disease: a view of metastasis;Redig;J Intern Med,2013

4. Epigenetic control of epithelial-mesenchymal-transition in human cancer;Kiesslich;Mol Clin Oncol,2012

5. Epithelial-mesenchymal transitions in tumour progression;Thiery;Nat Rev Cancer,2002

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TAM family kinases as therapeutic targets at the interface of cancer and immunity;Nature Reviews Clinical Oncology;2023-09-04

2. The Role of AXL Receptor Tyrosine Kinase in Cancer Cell Plasticity and Therapy Resistance;Biomarkers of the Tumor Microenvironment;2022

3. Receptor-Defined Breast Cancer in Five East African Countries and Its Implications for Treatment: Systematic Review and Meta-Analysis;JCO Global Oncology;2021-02

4. AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations;International Journal of Molecular Sciences;2020-11-10

5. Combining kinase inhibitors for optimally co‐targeting cancer and drug escape by exploitation of drug target promiscuities;Drug Development Research;2020-09-15